On February 28, 2024, Francois Brisebois, an analyst at Oppenheimer, once again expressed confidence in Tarsus Pharmaceuticals, giving it an Outperform rating and increasing the price target to $59 from $55. This optimistic view is based on the potential for Tarsus Pharmaceuticals to provide investors with a substantial return on their investment. The company’s recent strong performance, as outlined in the Q4 2023 earnings call, has shown impressive revenue growth and successful adoption of its products by healthcare providers. Francois Brisebois’ unwavering support for Tarsus Pharmaceuticals indicates a positive outlook on the company’s future prospects and market performance.
TARS Stock Price Surges by 18.28% on February 28, 2024: Strong Momentum and Potential for Growth
On February 28, 2024, TARS stock had an impressive performance, with the price of shares increasing by $6.06 since the market last closed, representing a significant 18.28% rise, closing at $39.22. Additionally, in after-hours trading, the stock continued to climb, rising by $0.78.
One notable aspect of TARS stock’s performance on this day is its price momentum. The stock is trading near the top of its 52-week range, indicating strong upward momentum. Furthermore, it is also trading above its 200-day simple moving average, which is a positive sign for investors as it suggests that the stock is in an uptrend over the long term.
Investors may want to keep an eye on this stock as it continues to show strength and potential for further growth.
TARS Stock Performance Review: Total Revenue Decreases, Net Income Improves
On February 28, 2024, TARS stock experienced a mixed performance based on the company’s financial results. According to data from CNN Money, TARS reported a total revenue of $17.45 million over the past year, which decreased by 32.42% compared to the previous year. However, the total revenue saw a significant increase of 598.88% since the last quarter, reaching $13.08 million.
The net income for TARS was reported as -$135.89 million over the past year, reflecting a decrease of 118.86% compared to the previous year. In the last quarter, the net income was reported as -$41.90 million, showing a decrease of 7.03% compared to the previous quarter.
In terms of earnings per share (EPS), TARS reported a figure of -$4.62 over the past year, which represents a decrease of 83.38% compared to the previous year. The EPS for the last quarter was reported as -$1.31, showing no change compared to the previous quarter.
Overall, TARS stock performance on February 28, 2024, was impacted by the significant decrease in total revenue and net income over the past year. However, the company managed to show some improvement in total revenue compared to the previous quarter. Investors may want to closely monitor TARS stock in the coming months to assess its financial performance and potential for growth.
